Description
The BP-1 monoclonal antibody specifically recognizes CD249 which is also known as, 6C3/BP-1, Enpep, or Ly-51. CD249 is a glycoprotein cell-surface differentiation antigen, which was originally identified on pre-B cell lymphomas (spontaneous and chemical- or retrovirus- transformed, in vitro and in vivo). CD249 is a homodimeric cell-surface glycoprotein with 140-kDa subunits that has been identified to possess aminopeptidase A (APA) activity. The same antigen is expressed at high levels on bone marrow stromal cell lines which support in vitro B lymphopoieses, on thymic dendritic cells and cortical epithelial cells, and on a wide variety of mouse and rat tissues known to possess APA activity. Subsets of normal bone marrow pre-B and B lymphocytes express low levels of CD249 which is rapidly up-regulated on the pre-B cells in the presence of IL-7. A role for the CD249 molecule in the IL-7-driven proliferation of B cell precursors has been postulated. However, B-cell abnormalities were not detected in CD249/Ly-51-deficient mice. Mature B lymphocytes, thymocytes, peripheral T lymphocytes, erythroid cells, and myeloid cells (with the exception of thymic dendritic cells) do not express CD249.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV786 under optimal conditions that minimize unconjugated dye and antibody.
1. This antibody was developed for use in flow cytometry.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Researchers should determine the optimal concentration of this reagent for their individual applications.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. BD Horizon Brilliant Violet 786 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
9. Cy is a trademark of GE Healthcare.
10. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
